Friday, July 10, 2020

Xencor Links With Atreca

Monrovia, California-based biopharmaceuticals developer Xencor says it has linked with another biotechnology company, Atreca, to research, develop and commercialize T cell engaging bispecific antibodies as potential therapeutics in oncology. According to the companies, they will team in a three-year discovery program, where Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells. The two said that up to two joint programs will be mutually selected for further development and commercialization, with each partner sharing 50 percent of costs and profits.

---